Results 31 to 40 of about 68,603 (270)

CD20 and CD37 antibodies synergize to activate complement by Fc-mediated clustering

open access: yesHaematologica, 2019
CD20 monoclonal antibody therapies have significantly improved the outlook for patients with B-cell malignancies. However, many patients acquire resistance, demonstrating the need for new and improved drugs.
Simone C. Oostindie   +16 more
doaj   +1 more source

Lamprey Variable Lymphocyte Receptors Mediate Complement-Dependent Cytotoxicity [PDF]

open access: yesThe Journal of Immunology, 2013
Abstract An alternative adaptive-immune system is present in the most basal vertebrates—lampreys and hagfish—the only surviving jawless vertebrates. These eel-like fish use leucine-rich repeat–based receptors for Ag recognition instead of the Ig-based receptors used in jawed vertebrates.
Fenfang, Wu   +12 more
openaire   +2 more sources

Towards effective immunotherapy of myeloma: enhanced elimination of myeloma cells by combination of lenalidomide with the human CD38 monoclonal antibody daratumumab

open access: yesHaematologica, 2011
Background In our efforts to develop novel effective treatment regimens for multiple myeloma we evaluated the potential benefits of combining the immunomodulatory drug lenalidomide with daratumumab.
Michael. S. van der Veer   +7 more
doaj   +1 more source

Endovascular trophoblast expresses CD59 to evade complement-dependent cytotoxicity [PDF]

open access: yesMolecular and Cellular Endocrinology, 2019
In the human placenta, extravillous trophoblasts (EVTs) invade maternal decidual tissues (interstitial trophoblasts) and maternal spiral arteries (endovascular trophoblasts). Although endovascular trophoblasts are directly exposed to maternal blood containing complement components, they are not eliminated by complement-dependent cytotoxicity (CDC).
Masashi Ueda   +9 more
openaire   +2 more sources

Anti-HER2 Cancer-Specific mAb, H2Mab-250-hG1, Possesses Higher Complement-Dependent Cytotoxicity than Trastuzumab

open access: greenInternational Journal of Molecular Sciences
Yukinari Kato   +2 more
exaly   +2 more sources

The in vivo mechanism of action of CD20 monoclonal antibodies depends on local tumor burden

open access: yesHaematologica, 2011
Background CD20 monoclonal antibodies are widely used in clinical practice. Antibody-dependent cellular cytotoxicity, complement-dependent cytotoxicity and direct cell death have been suggested to be important effector functions for CD20 antibodies ...
Peter Boross   +10 more
doaj   +1 more source

Enhanced CDC of B cell chronic lymphocytic leukemia cells mediated by rituximab combined with a novel anti-complement factor H antibody. [PDF]

open access: yesPLoS ONE, 2017
Rituximab therapy for B cell chronic lymphocytic leukemia (B-CLL) has met with mixed success. Among several factors to which resistance can be attributed is failure to activate complement dependent cytotoxicity (CDC) due to protective complement ...
Mark T Winkler   +7 more
doaj   +1 more source

Variable sensitivity to complement-dependent cytotoxicity in murine models of neuromyelitis optica. [PDF]

open access: yesJ Neuroinflammation, 2016
Studies of neuromyelitis optica (NMO), an autoimmune disease of the central nervous system (CNS), have demonstrated that autoantibodies against the water channel aquaporin-4 (AQP4) induce astrocyte damage through complement-dependent cytotoxicity (CDC).
Liu Y   +5 more
europepmc   +3 more sources

Applicability of Traditional In Vitro Toxicity Tests for Assessing Adverse Effects of Monoclonal Antibodies: A Case Study of Rituximab and Trastuzumab

open access: yesAntibodies, 2018
Monoclonal antibody (mAb) therapeutics have a promising outlook within the pharmaceutical industry having made positive strides in both research and development as well as commercialisation, however this development has been hampered by manufacturing ...
Arathi Kizhedath   +2 more
doaj   +1 more source

The Role of Complement in the Mechanism of Action of Therapeutic Anti-Cancer mAbs

open access: yesAntibodies, 2020
Unconjugated anti-cancer IgG1 monoclonal antibodies (mAbs) activate antibody-dependent cellular cytotoxicity (ADCC) by natural killer (NK) cells and antibody-dependent cellular phagocytosis (ADCP) by macrophages, and these activities are thought to be ...
Josée Golay, Ronald P. Taylor
doaj   +1 more source

Home - About - Disclaimer - Privacy